{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Central+Nervous+System+Tumor&page=5", "query": { "condition": "Relapsed Central Nervous System Tumor", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 174, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Central+Nervous+System+Tumor&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Central+Nervous+System+Tumor&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T08:09:30.442Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03478462", "title": "Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric Solid Tumor", "Pediatric Lymphoma", "Pediatric Brain Tumor", "DIPG", "Neuroblastoma", "Ewing Sarcoma", "Rhabdomyosarcoma", "Osteosarcoma" ], "interventions": [ { "name": "CLR 131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2019-04-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 6, "location_summary": "Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478462" }, { "nct_id": "NCT01528046", "title": "Metformin in Children With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Primary Brain Tumors" ], "interventions": [ { "name": "Vincristine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 26, "start_date": "2012-09-24", "completion_date": "2020-02-03", "has_results": false, "last_update_posted_date": "2023-01-13", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 14, "location_summary": "Hartford, Connecticut • Wilmington, Delaware • Gainesville, Florida + 10 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01528046" }, { "nct_id": "NCT00066599", "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Neutropenia", "Sarcoma" ], "interventions": [ { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": null, "start_date": "2003-06", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 7, "location_summary": "Orange, California • San Diego, California • Bethesda, Maryland + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066599" }, { "nct_id": "NCT01130623", "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Neuroblastoma", "Wilms Tumor", "Osteosarcoma", "Brain Tumor" ], "interventions": [ { "name": "Pazopanib (GW786034)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 0, "start_date": "2010-05-10", "completion_date": "2011-11-18", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130623" }, { "nct_id": "NCT04049669", "title": "Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Medulloblastoma", "Ependymoma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Partial Radiation", "type": "RADIATION" }, { "name": "Full-dose Radiation", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Theodore S. Johnson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 130, "start_date": "2019-10-02", "completion_date": "2027-10-02", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 5, "location_summary": "Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Druid Hills", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049669" }, { "nct_id": "NCT01884740", "title": "Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Fibrillary Astrocytoma of Brain", "Glioma of Brainstem", "Anaplastic Astrocytoma", "Pilomyxoid Astrocytoma", "Mixed Oligodendroglioma-Astrocytoma", "Brain Stem Glioma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "SIACI of Erbitux and Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 13, "start_date": "2013-06", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01884740" }, { "nct_id": "NCT04106219", "title": "A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "LY3295668 Erbumine", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 71, "start_date": "2020-06-11", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106219" }, { "nct_id": "NCT00066248", "title": "Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumors", "Cachexia", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cyproheptadine hydrochloride", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 70, "start_date": "2003-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 40, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066248" }, { "nct_id": "NCT00750009", "title": "Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 583, "start_date": "2008-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00750009" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-06T08:09:30.442Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" } ] }